Last reviewed · How we verify
CYT005-AllQbG10
At a glance
| Generic name | CYT005-AllQbG10 |
|---|---|
| Sponsor | Cytos Biotechnology AG |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis (PHASE2)
- A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis (PHASE2)
- Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy (PHASE1, PHASE2)
- Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYT005-AllQbG10 CI brief — competitive landscape report
- CYT005-AllQbG10 updates RSS · CI watch RSS
- Cytos Biotechnology AG portfolio CI